

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-239) CREXAVIBART
 PRONUNCIATION krex a' vi bart
 THERAPEUTIC CLAIM Treatment of SARS-CoV-2 infection
 CHEMICAL NAME

1. Immunoglobulin G1 [442-leucine,448-serine,de-461-lysine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding domain) (human monoclonal C144 γ 1-chain), disulfide with human monoclonal C144 λ -chain, dimer (Source: CAS)

STRUCTURAL FORMULA

Heavy chain X, X'

EVQLVESGGG	LIQPGGSLRL	SCAASGFTVS	NNYMSWVRQA	PGKGLEWVSV	50
IYSGGSTYYA	DSVKGRFTIS	RDKSKNTLYL	QMNSLRAEDT	AVYYCAREGE	100
VEGYNDFWSG	YSRDRYYFDY	WGQGLTVTVS	SASTKGPSVF	PLAPSSKSTS	150
GGTAALGCLV	KDYFPEPVTV	SWNSGALTSG	VHTFPAVLQS	SGLYSLSSVV	200
TVPSSSLGTQ	TYICNVNHKP	SNTKVDKRVE	PKSCDKTHTC	PPCPAPPELLG	250
GPSVFLFPPK	PKDTLMISRT	PEVTCVVVDV	SHEDPEVKFN	WYVDGVEVHN	300
AKTKPREEQY	NSTYRVVSVL	TVLHQDWLNG	KEYKCKVSNK	ALPAPIEKTI	350
SKAKGQPREP	QVYTLPPSRE	EMTKNQVSLT	CLVKGFYPSD	IAVEWESNGQ	400
PENNYKTPPP	VLDSDGSEFFL	YSKLTVDKSR	WQQGNVFSCS	VLHEALHSHY	450
TQKSLSLSPG					454

Light chain X', X''

QSALTQPASV	SGSPGQSITI	SCTGTSSDVG	GYNYVSWYQQ	HPGKAPKLMI	50'
YDVSNRPSGV	SNRFSGSKSG	NTASLTISGL	QAEDEADYYC	SSYTSSSTRV	100'
FGTGTKVTVL	GQPKAAPSVT	LFPPSSEELQ	ANKATLVCLI	SDFYPGAATV	150'
AWKADSSPVK	AGVETTPPSK	QSNNKYAASS	YLSLTPEQWK	SHRSYSCQVT	200'
HEGSTVEKTV	APTECS				215'

Disulfide bridges

22'-90'	22'''-90'''	22-95	22''-95''	138'-197'	138'''-197'''	158-214	158''-214''
234-215'	234''-215''	240-240''	243-243''	275-335	275'''-335'''	381-439	381-439''

Glycosylation sites (N)

MOLECULAR FORMULA $C_{6490}H_{9992}N_{1728}O_{2064}S_{42}$ (EXPASY)

MOLECULAR WEIGHT 146.57 kDa (EXPASY)

TRADEMARK None as yet

SPONSOR Bristol Myers Squibb

CODE DESIGNATIONS BMS-986413, IM051, C144-LS

CAS REGISTRY NUMBER 2599039-61-7

UNII ME6UG23L4A

WHO NUMBER

12362

gbk